Equities analysts expect that Endologix, Inc. (NASDAQ:ELGX) will post sales of $30.85 million for the current quarter, Zacks reports. Five analysts have provided estimates for Endologix’s earnings, with estimates ranging from $29.50 million to $31.40 million. Endologix posted sales of $45.99 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 32.9%. The business is expected to issue its next earnings results on Tuesday, November 6th.

On average, analysts expect that Endologix will report full year sales of $149.19 million for the current financial year, with estimates ranging from $146.80 million to $150.67 million. For the next financial year, analysts forecast that the company will report sales of $142.06 million per share, with estimates ranging from $135.48 million to $155.10 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Endologix.

Endologix (NASDAQ:ELGX) last announced its quarterly earnings results on Thursday, August 9th. The medical instruments supplier reported ($0.18) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.18). Endologix had a negative net margin of 40.92% and a negative return on equity of 69.06%. The firm had revenue of $44.70 million for the quarter, compared to analyst estimates of $44.43 million. During the same period last year, the business earned ($0.10) EPS. Endologix’s revenue for the quarter was down 8.0% compared to the same quarter last year.

ELGX has been the topic of several research analyst reports. BidaskClub lowered shares of Endologix from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 25th. BTIG Research dropped their price objective on shares of Endologix to $4.00 and set a “buy” rating on the stock in a research note on Thursday, August 23rd. ValuEngine upgraded shares of Endologix from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Stifel Nicolaus lifted their price objective on shares of Endologix from $4.50 to $5.00 and gave the company a “hold” rating in a research note on Monday, May 21st. Finally, BMO Capital Markets restated a “hold” rating and issued a $4.00 price objective (down from $6.50) on shares of Endologix in a research note on Friday, August 10th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $4.00.

In other Endologix news, CFO Vaseem Mahboob acquired 30,000 shares of the company’s stock in a transaction on Thursday, August 16th. The shares were bought at an average cost of $2.43 per share, for a total transaction of $72,900.00. Following the completion of the purchase, the chief financial officer now owns 146,812 shares in the company, valued at approximately $356,753.16. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 3.90% of the company’s stock.

Several institutional investors have recently modified their holdings of ELGX. BlackRock Inc. increased its stake in shares of Endologix by 11.1% during the second quarter. BlackRock Inc. now owns 5,644,438 shares of the medical instruments supplier’s stock worth $31,948,000 after acquiring an additional 565,175 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in shares of Endologix by 14.0% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,431,962 shares of the medical instruments supplier’s stock worth $8,105,000 after acquiring an additional 175,970 shares during the period. Altrinsic Global Advisors LLC increased its stake in shares of Endologix by 9.5% during the first quarter. Altrinsic Global Advisors LLC now owns 1,035,000 shares of the medical instruments supplier’s stock worth $4,378,000 after acquiring an additional 90,000 shares during the period. Engineers Gate Manager LP acquired a new position in shares of Endologix during the second quarter worth about $442,000. Finally, C WorldWide Group Holding A S increased its stake in shares of Endologix by 22.3% during the second quarter. C WorldWide Group Holding A S now owns 364,464 shares of the medical instruments supplier’s stock worth $2,063,000 after acquiring an additional 66,486 shares during the period. Institutional investors and hedge funds own 93.83% of the company’s stock.

Shares of NASDAQ:ELGX opened at $2.20 on Monday. Endologix has a 12 month low of $2.14 and a 12 month high of $6.72. The company has a current ratio of 1.90, a quick ratio of 1.20 and a debt-to-equity ratio of 5.37. The firm has a market cap of $186.36 million and a P/E ratio of -4.58.

Endologix Company Profile

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.

Further Reading: Trading Strategy Examples and Plans

Get a free copy of the Zacks research report on Endologix (ELGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.